Pharmaceutical company Summit Therapeutics is standing out today, surging to $20.45 and marking a 10.6% change. In comparison ...

Fintel reports that on February 28, 2025, Goldman Sachs initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

Goldman Sachs initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target Discover the Best Stocks and Maximize ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics sank -13.4% today, compared to the S&P 500's day change of -0.0%. Today's losers may turn out to be ...